Tactile Systems Sees 12% Revenue Rise to $329.5M, Guides 8–11% Growth
Tactile Systems Technology posted 12% revenue growth to $329.5 million in 2025, closing the year with $83.4 million in cash. The company acquired Lymphotec to integrate fluid-monitoring technology and expects 8%–11% revenue growth in 2026 despite new Medicare prior-authorization requirements.
1. Full-Year 2025 Financial Results
Tactile Systems reported revenue of $329.5 million for fiscal 2025, a 12% increase over the prior year, driven by solid device sales and expanded patient access. The company ended the period with $83.4 million in cash and equivalents, reinforcing its balance sheet strength for ongoing investments.
2. Lymphotec Acquisition and Integration
In early 2025, Tactile Systems acquired Lymphotec to gain its fluid-monitoring technology aimed at undiagnosed lymphedema patients. Integration into the existing commercial platform is expected to streamline patient surveillance and accelerate therapy initiation.
3. Productivity Investments
Investments made in 2024 in a new customer relationship management system and an expanded sales headcount began yielding productivity gains in 2025. Enhanced data tracking and a larger field team contributed to improved sales efficiency and higher treatment adoption rates.
4. Guidance for 2026 and Medicare Impact
The company issued revenue guidance of 8%–11% growth for 2026, reflecting confidence in its product pipeline and sales initiatives. This outlook incorporates a potential headwind from a new Medicare prior-authorization requirement for pneumatic compression devices, which may slow near-term reimbursement.